CDKN2A and neoplasm: Our results showing frequent loss of p16 expression in the entire tumor or focally (7/9 H3 K27M and 6/8 wt cases) have implications that should be considered more largely, as they may open the path for therapies targeting the p16 pathway (e.g., CDK4 or cyclin D1) in this population.